DelistingSep 30, 2026, 04:31 PM
Outlook Therapeutics Faces Nasdaq Delisting Warning Over Low Stock Price
AI Summary
Outlook Therapeutics, Inc. has received a notification from Nasdaq that its common stock has fallen below the $1.00 minimum closing bid price requirement for 30 consecutive business days. The company has 180 days, until March 24, 2027, to regain compliance. If it fails to do so, it may be eligible for an additional 180-day period under certain conditions, or its stock could face delisting, though an appeal process is available.
Key Highlights
- Outlook Therapeutics received a notification from Nasdaq indicating its common stock has closed below $1.00 for 30 consecutive business days.
- The company has until March 24, 2027, to regain compliance by having its stock close at or above $1.00 for ten consecutive business days.
- Failure to comply may result in an additional 180-day period if certain conditions are met, including a reverse stock split.
- If compliance is not achieved, the stock may be subject to delisting, with an option to appeal to a Nasdaq hearings panel.
Price Impact
More from OTLK